Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
All Congress filingsSearch insider filingsEarnings calendarWatchlist
MORE TOOLS
Gold IntelligenceSilver IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeAll Congress filingsSearch insider filings
More research tools
ExploreGold IntelligenceSilver IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…

CongressSearchHomeWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
LOOK INSIDE THE BUSINESS

Company financials.

Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.

View IGC insider activity ↗

IGCIGC Pharma, Inc.

THE LATEST REPORTED YEAR

The company reported a loss.

$7.12M net loss for the year ended March 31, 2025. These are reported results, not a forecast or a stock recommendation.

Revenue$1.27MYear ended March 31, 2025
Profit or loss-$7.12MYear ended March 31, 2025
Cash from the business-$4.8MYear ended March 31, 2025
Total assets$9.5MAs of June 30, 2026
Total liabilities$3.36MAs of June 30, 2026
Cash & equivalents$331KAs of June 30, 2026
THE BUSINESS BEHIND THE TICKER

Revenue, over time.

Latest-filed standard financial facts · USD

$2.19M
2018-03
$5.12M
2019-03
$4.07M
2020-03
$898K
2021-03
$397K
2022-03
$911K
2023-03
$1.35M
2024-03
$1.27M
2025-03

Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.

From the filing

Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.

Reported periodReported valueFiledSource
April 1, 2024 – March 31, 2025$1,271,000June 27, 202510-K ↗
April 1, 2023 – March 31, 2024$1,345,000June 27, 202510-K ↗
April 1, 2022 – March 31, 2023$911,000June 24, 202410-K ↗
April 1, 2021 – March 31, 2022$397,000July 7, 202310-K ↗
April 1, 2020 – March 31, 2021$898,000June 23, 202210-K ↗
April 1, 2019 – March 31, 2020$4,072,000June 14, 202110-K ↗
April 1, 2018 – March 31, 2019$5,116,000July 13, 202010-K ↗
April 1, 2017 – March 31, 2018$2,193,000June 14, 201910-K ↗
Source and calculation details

One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.

Concept: us-gaap:Revenues · Retrieved October 15, 2026

Response SHA-256: b5e6159ba110e204ee8261b531c546158153a9053fcdb3ca873d1eff8c2a793e

SEC company facts

Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.